Contents of resolutions adopted by the Extraordinary General Meeting on January 4, 2024, dismissal and appointment of a member of the Company's Supervisory Board

Current Report No. 1/2024

Date of preparation: January 4, 2024

Subject: Contents of resolutions adopted by the Extraordinary General Meeting on January 4, 2024, dismissal and appointment of a member of the Company's Supervisory Board

Legal basis: Article 56 (1) (2) of the Act on Offering - current and periodic information

The Management Board of Captor Therapeutics S.A., based in Wrocław, Poland (the "Company"), hereby provides the contents of the resolutions adopted by the Extraordinary General Meeting of the Company on January 4, 2024 (the "EGM").

The EGM did not waive consideration of any of the items on the planned agenda. There were no objections to the adopted resolutions.

Under the adopted resolutions the EGM dismissed Mr. Florent Gros from the Company's Supervisory Board and appointed Mr. Charles Kunsch to the Company's Supervisory Board.

The Company attaches a resume of Mr. Charles Kunsch describing his previous positions and career.

Mr. Charles Kunsch submitted a statement (attached), confirming that he does not conduct activities competitive to those conducted by the Company, and does not participate in a competitive company/partnership as a partner in a civil partnership, commercial partnership or company, as well as does not participate in a competitive legal person as a member of its body. Mr. Charles Kunsch, according to the statement, is not registered in the Register of Insolvent Debtors maintained under the National Court Register Act.

Detailed legal basis:

§ 5(1)(4) and (5) and § 19(1)(6) of the MFR on current and periodic information provided by issuers of securities and conditions for recognizing as equivalent information required by the laws of a non-member state.